You are here

Cat's Claw is Powerful Inhibitor and Reducer of Brain Plaques and Tangles

In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly

A natural plant extract known as PTI-00703 cat’s claw (Uncaria tomentosa) has been discovered to be a potent inhibitor and reducer of brain plaques and tangles. The 10-year-long study, just published in Scientific Reports, was led by brain aging and Alzheimer’s disease authority Alan Snow.

Using a variety of in vitro screening methods and brain plaque-producing transgenic mice, the researchers found that a reduction of brain plaque-load in the mice correlated directly with notable improvements in short-term memory. 

PTI-00703 cat’s claw, from an Amazonian rain forest plant, is extracted using a specific proprietary methodology that produces the strongest form of cat’s claw to effectively target brain plaque and tangle accumulation. The woody vine from which the extract comes regrows after it is harvested, thus replenishing the source.

The main components of PTI-00703 cat's claw entered the brain within two minutes of being in the blood. A major polyphenol ingredient, proanthocyanidin B2, reduced brain plaques in older transgenic mice by ~52–58% and in younger transgenic mice by ~74–83% over a three-month period. The brain-plaque reduction also led to a ~58% improvement in short-term memory.

Future human clinical trials will be required to validate and confirm the results obtained from the various in vitro and in vivo studies reported in the current investigation.

BioSpace, February 7, 2019

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug